Statin therapy and myocardial no-reflow
1Division of Cardiology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
British Journal of Pharmacology
|August 22, 2006
Summary
Statins, like simvastatin, offer cardiovascular protection beyond lipid lowering. This study reveals simvastatin activates mitochondrial K(ATP) channels to reduce myocardial no-reflow, a novel cardioprotective mechanism.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Mitochondrial Biology
Background:
- Statins (HMG-CoA reductase inhibitors) are key in cardiovascular disease treatment.
- Cardioprotective effects were initially attributed to lipid-lowering, but pleiotropic actions are now recognized.
- Statins exhibit anti-inflammatory and anti-apoptotic effects, and increase nitric oxide bioavailability.
Purpose of the Study:
- To elucidate a novel mechanism of statin action in cardiovascular disease.
- To investigate the effect of simvastatin on myocardial 'no-reflow' following ischemia and reperfusion.
- To explore the role of mitochondrial K(ATP) channels in statin-mediated cardioprotection.
Main Methods:
- Experimental models of ischemia and reperfusion injury.
- Assessment of myocardial 'no-reflow' phenomenon.
- Pharmacological activation of mitochondrial K(ATP) channels.
Main Results:
- Simvastatin significantly reduces myocardial 'no-reflow' after ischemia and reperfusion.
- This protective effect is mediated by the activation of the mitochondrial K(ATP) channel.
- Identifies a novel, non-lipid-lowering mechanism for statin cardioprotection.
Conclusions:
- Simvastatin's activation of mitochondrial K(ATP) channels represents a novel cardioprotective mechanism.
- These findings have significant implications for the therapeutic strategies in cardiovascular diseases.
- Statins' pleiotropic effects, including channel activation, are crucial for their cardiovascular benefits.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...